StreetInsider.com News Articles

Kairos Pharma reports positive interim data for prostate cancer drug

Tue, 06 Oct 2026 07:30:25 -0400

Kairos Pharma, Ltd. (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer.

The interim analysis showed a statistically significant difference in progression-free survival between patients treated with ENV-105 plus apalutamide and those treated with apalutamide alone. Median progression-free survival was 17.7 months with the combination compared with 2 months with apalutamide alone, with a p-value of 0.0008.

Following the interim results, Kairos Pharma modified the Phase 2 protocol to enroll patients earlier in the course of disease progression. The modified protocol will

Form 8-K Kairos Pharma, LTD. For: Oct 06

Tue, 06 Oct 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20261006/27151884.html

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

Tue, 06 Oct 2026 07:30:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) between all patients in the trial treated with ENV-105 plus apalutamide and those treated with apalutamide alone. Median PFS was 17.7 months with the combination compared with 2 months with apalutamide alone (P=0.0008).

With the interim efficacy signal, Kairos Pharma

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

Tue, 06 Oct 2026 07:30:00 -0400

With the interim efficacy signal, Kairos Pharma

Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

Wed, 23 Sep 2026 08:00:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference. The conference is being held on Sept. 28 to Oct. 1 at the Sheraton Boston Hotel with sessions available on demand on the conference’s website.

Bhowmick will moderate an in-person only breakout session on Sept. 30 titled, “Winning the Race against Cancer Therapy Resistance,” focused on Kairos’

Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

Wed, 23 Sep 2026 08:00:00 -0400

Bhowmick will moderate an in-person only breakout session on Sept. 30 titled, “Winning the Race against Cancer Therapy Resistance,” focused on Kairos’

Form 8-K Kairos Pharma, LTD. For: Sep 14

Mon, 14 Sep 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260914/27058290.html

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Wed, 09 Sep 2026 08:00:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.

Presentation Date: September 14, 2026

Time: 4:00 PM Eastern Time (Holmes 1)

Webcast Link: Available Here

A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A replay

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Wed, 09 Sep 2026 08:00:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.

Presentation Date: September 14, 2026

Time: 4:00 PM Eastern Time (Holmes 1)

Webcast Link: Available Here

A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A replay

Form 8-K Kairos Pharma, LTD. For: Aug 21

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961810.html

Form 8-K Kairos Pharma, LTD. For: Aug 21

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961810.html

Kairos Pharma announces 1-for-7 reverse stock split

Fri, 21 Aug 2026 16:30:15 -0400

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced a 1-for-7 reverse stock split of its outstanding common shares, effective September 1, 2026 at 12:01 a.m. ET.

Shares are expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026, under the existing ticker symbol "KAPA" and a new CUSIP number of 48301N203.

Under the terms of the split, every seven shares of common stock will be automatically reclassified and combined into one share. No fractional shares will be issued; instead, holders entitled to a fraction will have their shares rounded up

Kairos Pharma announces 1-for-7 reverse stock split

Fri, 21 Aug 2026 16:30:15 -0400

Shares are expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026, under the existing ticker symbol "KAPA" and a new CUSIP number of 48301N203.

Kairos Pharma announces 1-for-7 reverse stock split

Fri, 21 Aug 2026 16:30:15 -0400

Shares are expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026, under the existing ticker symbol "KAPA" and a new CUSIP number of 48301N203.

Kairos Pharma announces 1-for-7 reverse stock split

Fri, 21 Aug 2026 16:30:15 -0400

Shares are expected to begin trading on the NYSE American on a split-adjusted basis at market open on September 1, 2026, under the existing ticker symbol "KAPA" and a new CUSIP number of 48301N203.

Kairos Pharma Announces 1-for-7 Reverse Stock Split